Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2020 | Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM

Amrita Krishnan • 23 Nov 2020
ASH 2020
Multiple Myeloma Antibodies Teclistamab

Amrita Krishnan, MD, City of Hope National Medical Center, Duarte, CA discusses the results of a relapsed/refractory multiple myeloma (MM) trial (NCT03145181) of teclistamab, a bispecific BCMA-CD3 antibody that activates T-cell killing of BCMA-expressing MM cells. Subcutaneous (SC) and intravenous administration was investigated in the process of establishing a recommended Phase II dose. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Amrita Krishnan

The most important decision for community oncologists when managing newly diagnosed myeloma
1:30
The most important decision for community oncologists when managing newly diagnosed myeloma
Amrita Krishnan • 29 May 2026
Preparing community centers for the administration of bispecific antibodies
1:14
Preparing community centers for the administration of bispecific antibodies
Amrita Krishnan • 29 May 2026
Depth, duration, and risk: reaching consensus in newly diagnosed myeloma
1:56
Depth, duration, and risk: reaching consensus in newly diagnosed myeloma
Amrita Krishnan • 29 May 2026
Transplant versus T-cell redirecting therapies in the upfront setting for multiple myeloma
1:27
Transplant versus T-cell redirecting therapies in the upfront setting for multiple myeloma
Amrita Krishnan • 7 Dec 2025

Related Videos

Phase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myeloma
3:16
Phase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myeloma
Dean Smith • 25 Sep 2026
Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
3:29
Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
Aditya Nair • 25 Sep 2026
MRD-guided maintenance discontinuation in myeloma: long-term results from GEM2014MAIN
2:51
MRD-guided maintenance discontinuation in myeloma: long-term results from GEM2014MAIN
David Moreno • 25 Sep 2026
Infection-related mortality in myeloma: trends, disparities and prevention strategies
1:59
Infection-related mortality in myeloma: trends, disparities and prevention strategies
Shahzad Raza • 23 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals